HT
CLDX icon

Headlands Technologies’s Celldex Therapeutics CLDX Stock Holding History

Headlands Technologies’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,119
Closed -$125K – 728
2025
Q2 		$125K Buy
+6,119
New +$119K 0.01% 582
2025
Q1 		– Sell
-3,212
Closed -$81.2K – 1194
2024
Q4 		$81.2K Buy
+3,212
New +$87.3K 0.01% 708
2024
Q3 		– Sell
-9,182
Closed -$340K – 1234
2024
Q2 		$340K Buy
9,182
+5,669
+161% +$214K 0.04% 357
2024
Q1 		$147K Buy
+3,513
New +$144K 0.04% 453
2023
Q4 		– Sell
-718
Closed -$19.8K – 985
2023
Q3 		$19.8K Sell
718
-3,266
-82% -$102K 0.01% 586
2023
Q2 		$135K Buy
+3,984
New +$134K 0.04% 340

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Headlands Technologies's CLDX Position: Q3 2025 in Review

Headlands Technologies sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 6,119 shares — an estimated $125K sold.

Headlands Technologies first reported a position in CLDX in Q2 2023 and held it in 6 quarters. The position peaked at $340K in Q2 2024. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Headlands Technologies reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Headlands Technologies sold 6,119 Celldex Therapeutics shares in Q3 2025, an estimated $125K.
  • Headlands Technologies first reported a position in Celldex Therapeutics in Q2 2023 and held it in 6 quarters.
  • Headlands Technologies's Celldex Therapeutics position peaked at $340K in Q2 2024.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Headlands Technologies's 13F filing for Q3 2025, filed 12 Nov 2025.